Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Reports, 2024. Verfasst von Anang Agung Chrisnanda und 1 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Famotidine has emerged as a candidate for COVID-19 treatment, with various studies investigating its impact on the virus. These studies have reported encouraging results, suggesting that famotidine might contribute to fighting COVID-19 by potentially blocking histamine release, TMPRSS, and fortifying glycocalyx. Clinical trials aimed at assessing the effectiveness of famotidine in patients with COVID-19 have observed that it contributed to quicker alleviation of symptoms and reduction in inflammation, without compromising the body's immunity against SARS-CoV-2. However, in the case of patients with severe illness, famotidine's use did not significantly enhance survival rates. Although further investigation is necessary, famotidine has shown promise in alleviating symptoms and reducing inflammation in COVID-19 cases.
Zitieren
APA
Chrisnanda, A. A., & Saputro, A. H. (2024). Famotidine for COVID-19. Pharmacy Reports. https://doi.org/10.51511/pr.10
Vancouver
Chrisnanda AA, Saputro AH. Famotidine for COVID-19. Pharmacy Reports. 2024. doi:10.51511/pr.10
BibTeX
@article{Chrisnanda2024,
author = {Chrisnanda, Anang Agung and Saputro, Anjar Hermadi},
title = {Famotidine for COVID-19},
journal = {Pharmacy Reports},
year = {2024},
doi = {10.51511/pr.10}
}
EUVIMED